Screening of Rubella Virus, Cytomegalovirus, Hepatitis B Virus, Hepatitis C Virus, HIV, Syphilis, and

Fatih Mehmet Akıllı, Fatih Demir, Taylan Onat

Abstract read

In one paragraph

Article in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Fatih Mehmet AkıllıDepartment of Medical Microbiology, Sincan Training and Research Hospital, Health Sciences University, Ankara 34668, Turkey.ORCID 0000-0001-8541-7742

Fatih DemirDepartment of Obstetrics and Gynecology, Sincan Training and Research Hospital, Health Sciences University, Ankara 34668, Turkey.ORCID 0000-0001-8975-8368

Taylan OnatDepartment of Obstetrics and Gynecology, Sincan Training and Research Hospital, Health Sciences University, Ankara 34668, Turkey.ORCID 0000-0002-8920-1444

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TORCH pathogens are often asymptomatic in healthy adults but can cause foetal death when transmitted during pregnancy; therefore, accurate regional data are essential for screening. This study aimed to determine first-trimester TORCH seropositivity and to inform the development of hospital-based and national screening algorithms. This study analysed test results from 7481 pregnant women aged 15-49 years who participated between January 2020 and December 2024. TORCH serological results obtained using the MAGLUMI X3/X6 system (Snibe, Shenzhen, China) were analysed with Statistical Package for the Social Sciences. Anti-HCV positivity was 0.12% (9/7166), anti-

Indexed as

Antibodies, ViralPregnancy Complications, InfectiousAdolescentAdultAntibodies, BacterialAntibodies, ProtozoanChinaCytomegalovirusCytomegalovirus InfectionsFemaleHepacivirusHepatitis BHepatitis B virusHepatitis CHIV InfectionsHumansAntibodies, BacterialAntibodies, ProtozoanAntibodies, ViralImmunoglobulin Gcongenital infectionsepidemiologyprenatal screeningpublic healthseroprevalenceTORCHVDRL

Identifiers

PMID41754549

DOI10.3390/v18020206

PMCPMC12944900

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.